295 related articles for article (PubMed ID: 30091061)
21. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
Bone HG; Kiel DP; Lindsay RS; Lewiecki EM; Bolognese MA; Leary ET; Lowe W; McClung MR
J Clin Endocrinol Metab; 2007 Dec; 92(12):4671-7. PubMed ID: 17726081
[TBL] [Abstract][Full Text] [Related]
22. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
Ezhov MV; Safarova MS; Afanasieva OI; Pogorelova OA; Tripoten MI; Adamova IY; Konovalov GA; Balakhonova TV; Pokrovsky SN
Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
[TBL] [Abstract][Full Text] [Related]
23. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Gumprecht J; Gosho M; Budinski D; Hounslow N
Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
[TBL] [Abstract][Full Text] [Related]
24. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
Bots ML; Visseren FL; Evans GW; Riley WA; Revkin JH; Tegeler CH; Shear CL; Duggan WT; Vicari RM; Grobbee DE; Kastelein JJ;
Lancet; 2007 Jul; 370(9582):153-160. PubMed ID: 17630038
[TBL] [Abstract][Full Text] [Related]
25. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.
Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Gerasimidis T; Liapis CD
J Vasc Surg; 2010 Jan; 51(1):114-21. PubMed ID: 19837545
[TBL] [Abstract][Full Text] [Related]
26. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
[TBL] [Abstract][Full Text] [Related]
27. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
[TBL] [Abstract][Full Text] [Related]
28. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
[TBL] [Abstract][Full Text] [Related]
30. Marked low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis.
Kent SM; Coyle LC; Flaherty PJ; Markwood TT; Taylor AJ
Clin Cardiol; 2004 Jan; 27(1):17-21. PubMed ID: 14743850
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
[TBL] [Abstract][Full Text] [Related]
32. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study.
Lins RL; Matthys KE; Billiouw JM; Dratwa M; Dupont P; Lameire NH; Peeters PC; Stolear JC; Tielemans C; Maes B; Verpooten GA; Ducobu J; Carpentier YA
Clin Nephrol; 2004 Oct; 62(4):287-94. PubMed ID: 15524059
[TBL] [Abstract][Full Text] [Related]
33. Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia.
Zhao J; Yan HM; Li Y; Wang J; Han L; Wang ZH; Tang MX; Zhang W; Zhang Y; Zhong M
J Zhejiang Univ Sci B; 2015 May; 16(5):380-7. PubMed ID: 25990055
[TBL] [Abstract][Full Text] [Related]
34. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
35. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS).
Zhang J; Shao Y; Liu Y; Tao J
Cardiovasc Drugs Ther; 2018 Dec; 32(6):581-589. PubMed ID: 30187345
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the Efficacy of Atorvastatin on Patients with Carotid Plaque by an Innovative Ultrasonography.
Zhu YC; Jiang XZ; Bai QK; Deng SH; Zhang Y; Zhang ZP; Jiang Q
J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):830-837. PubMed ID: 30563776
[TBL] [Abstract][Full Text] [Related]
37. Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2-5.
Ramesh PL; Khandelwal P; Lakshmy R; Sinha A; Bagga A; Hari P
Pediatr Nephrol; 2023 Aug; 38(8):2763-2770. PubMed ID: 36780007
[TBL] [Abstract][Full Text] [Related]
38. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
Harris KP; Wheeler DC; Chong CC;
Kidney Int; 2002 Apr; 61(4):1469-74. PubMed ID: 11918754
[TBL] [Abstract][Full Text] [Related]
39. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
[TBL] [Abstract][Full Text] [Related]
40. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
